Literature DB >> 16081340

Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.

Takuya Nishimura1, Junichiro Hashimoto, Takayoshi Ohkubo, Masahiro Kikuya, Hirohito Metoki, Kei Asayama, Kazuhito Totsune, Yutaka Imai.   

Abstract

Our objective was to compare the efficacy and duration of action of 4 angiotensin II receptor blockers (ARBs)--losartan (25-100 mg), candesartan (2-12 mg), valsartan (40-80 mg), and telmisartan (10-40 mg)-in patients with essential hypertension using self-measurement of blood pressure at home (home BP) and to examine the differential effect of the four ARBs on home pulse pressure (home PP). After a 2-week run-in period, each of the 4 ARBs was assigned to subjects who were diagnosed as having hypertension on the basis of home BP and who were over 30 years old. The subjects were asked to take the ARB once daily in the morning and to measure home BP once in the evening and in the morning. We compared the efficacy of each ARB on home BP and home PP and assessed the duration of the BP-lowering effect using the morning effect versus evening effect ratio (M/E ratio). The antihypertensive effects of telmisartan on home systolic BP (SBP) both in the evening and in the morning and on home diastolic BP (DBP) in the morning were significantly greater than those of losartan. The effect of each ARB on home BP in the morning and in the evening was expressed as a ratio (M/E ratio). The M/E ratios of SBP/DBP in patients treated with losartan, candesartan, valsartan, and telmisartan were 0.49/0.16, 0.69/1.01, 0.82/0.88, and 0.88/0.88, respectively. The home PP-lowering effect was greater for valsartan and telmisartan than for losartan and candesartan in the morning. Among the 4 ARBs, the duration of the BP-lowering effect of losartan did not persist throughout 24 hr. The effects of the other 3 ARBs, in particular telmisartan, persisted over 24 hr when they were administered once daily in the morning. In addition, the duration of the PP-lowering effect was similar to that of the BP-lowering effect. Such long-acting property of several ARBs is essential for the modern antihypertensive treatment, and home BP measurements are useful for determining the duration of action of antihypertensive drugs. Losartan, 25 mg a day, which is usually used as an initial dose in Japan, is apparently insufficient to obtain adequate antihypertensive effect and sufficient duration of action.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081340     DOI: 10.1081/CEH-200067668

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  7 in total

Review 1.  Renin-angiotensin system in the kidney: What is new?

Authors:  Fernanda M Ferrão; Lucienne S Lara; Jennifer Lowe
Journal:  World J Nephrol       Date:  2014-08-06

2.  Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.

Authors:  Hisatoshi Bekki; Kiichiro Yamamoto; Masayoshi Sone; Tomoki Homma; Masashi Nakata; Masatoshi Nohara; Kei Fukami; Seiya Okuda; Sho-ichi Yamagishi
Journal:  Clin Cardiol       Date:  2011-02-01       Impact factor: 2.882

Review 3.  A personal history of research on hypertension From an encounter with hypertension to the development of hypertension practice based on out-of-clinic blood pressure measurements.

Authors:  Yutaka Imai
Journal:  Hypertens Res       Date:  2022-09-08       Impact factor: 5.528

Review 4.  New standards in hypertension and cardiovascular risk management: focus on telmisartan.

Authors:  Domenico Galzerano; Cristina Capogrosso; Sara Di Michele; Antonio Galzerano; Paola Paparello; Diana Lama; Carlo Gaudio
Journal:  Vasc Health Risk Manag       Date:  2010-03-24

Review 5.  Direct renin inhibitors: a new approach to antihypertensive drug treatment.

Authors:  C Venkata S Ram
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-08       Impact factor: 3.738

Review 6.  What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?

Authors:  Samir G Mallat
Journal:  Cardiovasc Diabetol       Date:  2012-04-10       Impact factor: 9.951

Review 7.  A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours.

Authors:  Philippe Gosse
Journal:  Vasc Health Risk Manag       Date:  2006
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.